Epidermal Growth Factor Receptor Inhibitors
Cross-source consensus on Epidermal Growth Factor Receptor Inhibitors from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Other
Highlighted claims
- EGFRIs are grouped into monoclonal antibodies and small-molecule tyrosine kinase inhibitors in the protocol. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFRIs are widely used targeted cancer therapies across several cancer types. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFRIs may be used alone or together with other anticancer treatments. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFR inhibition can disturb skin homeostasis because EGFR is important in epidermal keratinocytes and normal skin physiology. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol